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Purpose: To gain insight into the mechanisms underlying the transforming growth factor-beta induced (TGFBI)-related
corneal dystrophies and the influence of the Arg555Trp and Thr538Pro, TGFBI mutations on C-terminal cleavage and
cell endoplasmic reticulum (ER) stress were investigated.
Methods: The Arg555Trp and Thr538Pro mutations known to be associated with corneal dystrophy granular type I and
lattice corneal dystrophy, respectively, were introduced with the two-sequential PCR site-directed mutagenesis technique.
Wild-type and mutant TGFBI DNAs were cloned into the pcDNA3.1(-)/myc-his expression vector and overexpressed in
HeLa and human corneal epithelial cells (HCE) with transient transfection. Transfection efficiency was measured by the
expression of green fluorescent protein. Expression of the fusion proteins was measured with western blot analysis with
anti-c-myc-tag and anti-TGFBI antibodies. For cell ER stress studies, the expression levels of GRP78/BiP in HeLa cells
were analyzed with western blot analysis using an anti-GRP78 monoclonal antibody at 12, 24, and 48 h after either the
wild-type or mutant plasmid was transfected.
Results: Arg555Trp and Thr538Pro mutant TGFBIp were detected with the anti-c-myc and anti-TGFBI antibodies, while
wild-type TGFBIp was detected only with the anti-TGFBI antibody, indicating that the Arg555Trp and Thr538Pro
mutations prevent the C-terminal cleavage of TGFBIp. Moreover, no significant differences were seen in the expression
levels of GRP78/BiP between the mutant and wild-type TGFBIp groups, suggesting that mutations in TGFBIp are unlikely
to disrupt protein folding or induce cell ER stress.
Conclusions: This is the first time that the influence of TGFBI mutants on C-terminal cleavage and cell ER stress has
been illustrated. Corneal dystrophy–related mutations are more likely to disrupt the interaction of TGFBI with critical
binding proteins than affect the whole protein structure.
Corneal dystrophies (CDs) are a heterogeneous group of
diseases  characterized  by  bilateral,  non-inflammatory
deposits  in  corneal  layers,  which  result  in  corneal
opacification  and  visual  acuity  impairment.  Transforming
growth  factor-beta  induced  (TGFBI)-related  corneal
dystrophies  arise  from  heterozygous  mutations  in  the
transforming  growth  factor-beta  induced  gene  (TGFBI),
which is located on human chromosome 5q31. According to
the new international classification of corneal dystrophies, it
belongs  to  category  1  (clinically  and  histologically  well
defined dystrophy with identification of the gene and the
mutations)  and  includes  two  phenotypically  distinct  CDs:
lattice  corneal  dystrophy  (LCD)  and  granular  corneal
dystrophy  (GCD)  [1,2].  More  than  30  distinct  TGFBI
mutations have been identified in CDs [3], among which c.
1663C>T  (p.Arg555Trp)  is  the  most  frequent  mutation
resulting in GCD I according to several studies among various
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ethnic  groups  [4-9].  Recently,  a  novel  c.1613A>C
(p.Thr538Pro) mutation associated with LCD was identified
by our group [10].
The  TGFBI  protein  (TGFBIp,  also  known  as
keratoepithelin or βig-H3), which is encoded by the TGFBI
gene, is composed of 683 amino acids and has a molecular
mass of approximately 68 kDa. The protein is an extracellular
matrix (ECM) protein that contains an N-terminal secretory
signal peptide (1–23 aa), a cysteine-rich EMI domain (45–99
aa), four repeats of fasciclin-1-like (FAS1) domain (136–634
aa), and a C-terminal arginine-glycine-aspartic acid (RGD)
sequence (642–644 aa). Most of the mutations that have been
identified are located in the fourth FAS1 domain [3], such as
p.Arg555Trp and p.Thr538Pro. Although the mechanism by
which these mutations cause disease remains unknown, the
hypothesis of pathogenesis mainly consists of two aspects:
altering the binding interactions of TGFBIp with other critical
proteins and interfering with TGFBIp folding (Figure 1).
RGD, an integrin ligand, plays an important role in cell
adhesion, spreading, and apoptosis [11]. Wild-type TGFBIp
undergoes  C-terminal  cleavage  beside  the  RGD  sequence
after secretion, which is likely to leave the RGD exposed for
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1156interactions [11-13]. Cleavage is thought to be an important
step in TGFBI processing and allows TGFBIp to perform its
biologic function. However, to the best of our knowledge,
there  is  no  direct  evidence  regarding  this  proteolytic
processing in mutant TGFBI proteins.
Structure modeling studies predict that certain mutations
of TGFBI disrupt the TGFBIp structure, thereby leading to
misfolding of the protein [7,14]. Accumulation of unfolded
proteins  causes  endoplasmic  reticulum  (ER)  stress  and
triggers  an  ER  self-defense  response  called  the  unfolded
protein  response  (UPR),  which  ultimately  decreases  the
amount  of  unfolded  proteins  [15].  If  the  protective
mechanisms are not efficient enough to decrease the amount
of misfolded proteins and restore normal ER function, the
cells  will  die  via  apoptosis.  Glucose-regulated  protein
(GRP78, also known as BiP) is the major chaperone for ER
stress and plays a key role in protein folding [16,17]. Evidence
is emerging that ER stress–related toxicity plays a causative
role in disease development; this is especially true for diseases
caused by missense mutations in certain genes [18-22]. It is
therefore  necessary  to  investigate  the  effect  of  mutant
TGFBIp  on  cell  ER  stress,  thereby  shedding  light  on  the
pathogenesis of TGFBI-related corneal dystrophies.
Based on the two hypotheses, we investigated C-terminal
cleavage  and  cell  ER  stress  in  cells  expressing  with  two
mutant TGFBI proteins, c.1663C>T (p.Arg555Trp) and c.
1613A>C (p.Thr538Pro), which would result in GCD I and
LCD, respectively. The results show that the Arg555Trp and
Thr538Pro mutant TGFBI proteins are resistant to C-terminal
cleavage.  Furthermore,  the  overexpressed  Arg555Trp  and
Thr538Pro mutant TGFBI proteins were unlikely to induce
cell ER stress. This is the first time the influence of mutant
TGFBI proteins on C-terminal cleavage and cell ER stress has
been illustrated. These findings shed light on and increase
understanding  of  the  pathogenic  mechanisms  of  TGFBI-
related corneal dystrophies.
METHODS
Plasmid construction: The TGFBI cDNA clone was generated
with reverse transcription–polymerase chain reaction (RT–
PCR) from RNA isolated from a human HeLa cell line using
the primers TGFBI-WT-F and TGFBI-WT-R (Table 1) and
the SuperScript First-Strand Synthesis System for RT–PCR
kit (Invitrogen, Carlsbad, CA) following the manufacturer’s
instructions. Using these primers, the TGFBI stop codon was
removed,  and  5′-terminal  Xho  I/3′-terminal  Hind  III
restriction enzyme recognition sites were added. After double
digestion with Xho I/Hind III, the DNA products were ligated
into  the  pcDNA3.1(-)/myc-his  vector  (Invitrogen)  to
construct the pcTGFBI-WT-myc plasmid.
The mutations (T538P and R555W) were introduced with
the two-sequential PCR site-directed mutagenesis technique
(Figure 2). In the first PCR, the TGFBI-T538P/R555W-I and
TGFBI-T538P/R555W-II  fragments  were  amplified
individually with pcTGFBI-WT-myc as a template. In the
second PCR, full-length mutant TGFBI was amplified by
primers  TGFBI-WT-F  and  TGFBI-WT-R  with  purified
TGFBI-T538P/R555W-I and II as the DNA templates. PCR
Figure  1.  Schematic  of  proposed
mechanism  of  TGFBI-related  corneal
dystrophies  in  present  study.  The
hypothesis of pathogenesis of TGFBI-
related  corneal  dystrophies  mainly
consists  of  two  aspects:  altering  the
binding  interactions  of  TGFBIp  with
other  critical  proteins  and  interfering
with the TGFBIp folding. The influence
of  TGFBI  mutations  on  C-terminal
cleavage  and  cell  endoplasmic
reticulum  stress  investigated  in  the
present study was based on the aspects
of the hypothesis. The mechanism by
which  these  mutations  cause  disease
remains unknown, as indicated by the
dashed arrow.
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1157was performed in a 50 μl reaction mixture containing 100 ng
template DNA, 1 μM of each primer (Table 1), and 2.5 U DNA
Polymerase (AccuPrime Taq DNA Polymerase High Fidelity,
Invitrogen)  in  the  1×  PCR  buffer  provided  by  the
manufacturer. The thermocycling program was as follows:
initial denaturation at 94 °C for 5 min; followed by 30 cycles
of denaturation at 94 °C for 1 min, annealing at 65 °C for 1
min, and elongation at 68 °C for 3 min (for >1 kb PCR product)
or 1.5 min (for <1 kb PCR product); and 5 min of final
extension at 68 °C. The PCR products were gel-purified using
the AxyPrep DNA Gel Extraction Kit (Axygen, Union City,
CA) following the manufacturer’s instructions. After double
digestion with Xho I/Hind III, the purified products were
ligated into the pcDNA3.1(-)/myc-his vector to construct the
pcTGFBI-T538P/R555W-myc plasmids. The plasmids were
transformed  into  DH5а  chemically  competent  cells  and
seeded onto 1% LB agar plates supplemented with ampicillin.
After 18 h of incubation, 12 colonies were picked from each
sample and cultured in LB medium with 200 rpm/min shaking
overnight. The plasmid DNA was extracted using the Qiagen
Plasmid Midi Kit (Qiagen, Hilden, Germany) following the
manufacturer’s  instructions.  The  sequences  of  all  of  the
constructs were verified with direct sequencing.
Cell  culture  and  transient  transfection:  HeLa  cells  were
cultured  in  DMEM  medium  containing  10%  fetal  bovine
serum  (FBS;  Invitrogen)  and  antibiotics.  Human  corneal
epithelial (HCE) cells were grown in DMEM/F12 medium
containing 10% FBS, 5 µg/ml insulin (Sigma, St. Louis, MO),
10 ng/ml epidermal growth factor (EGF; Invitrogen), and
antibiotics. All cells were incubated at 37 °C in a humidified
atmosphere containing 5% CO2, and 0.8 or 2×106 cells were
seeded onto 60 mm or 100 mm dishes and grown for 18 h
(HeLa)  or  22  h  (HCE)  in  antibiotic-free  medium  before
transfection.  When  the  cells  were  grown  to  90%–95%
confluence, the cultures were transfected with 4.5 µg TGFBI
plasmids and 4.5 µg pEGFP-N1 vector (Clontech, Mountain
View, CA) using 30 µl Lipofectamine 2000 (Invitrogen) in
12 ml serum-free medium (100 mm dish) according to the
manufacturer’s instructions. The cells were incubated at 37 °C
in a 5% CO2 incubator for 4 h, and then the medium was
replaced with fresh culture medium containing 10% FBS. The
transfection efficiency was measured by the expression levels
of  the  enhanced  green  fluorescent  protein,  which  was
visualized directly with fluorescence microscopy.
For cell ER stress study, tunicamycin (T7765; Sigma)
was chosen as a positive inducer [23]. The expression levels
of GRP78 proteins were examined 18 h after treatment with
or  without  5  μg/ml  tunicamycin.  Dimethyl  sulphoxide
(DMSO) was used as solvent.
Western  blotting:  For  extracellular  protein  analysis,  the
culture medium was replaced with serum-free medium 48 h
post-transfection  to  eliminate  the  interference  of  TGFBIp
from FBS. Another 48 h later, the serum-free medium was
collected and concentrated with 15 centrifugal filter devices
(Amicon Ultra 30K NMWL device; Millipore, Boston, MA)
according  to  the  manufacturer’s  instructions.  For  the
intracellular protein analysis, the cells were harvested at 12,
24, and 48 h after transfection. After being washed with 1×
PBS, cells were lysed with a complete lysis kit (Roche, Basel,
Switzerland)  following  the  instruction  manual.  Protein
concentrations were determined using a BCA Protein Assay
Kit (Thermo Scientific, Waltham, MA). For sodium dodecyl
sulfate PAGE (SDS–PAGE), 5× SDS was diluted 1:4 with the
protein extract, and the samples were boiled for 10 min. Equal
amounts of protein were subjected to electrophoresis on 8%
SDS–PAGE  gels  and  transferred  to  a  polyvinylidene
difluoride  membrane  (Millipore,  Boston,  MA).  The
membrane was blocked with 5% nonfat dry milk in 1× Tris-
buffered saline buffer containing 0.1% Tween-20 (TBST) for
2 h at room temperature and then incubated overnight at 4 °C
with primary antibody. After being washed with 1× TBST for
TABLE 1. PRIMERS USED FOR PCR.
Amplified fragments Primer name Primer sequence (5′>3′)
TGFBI-WT TGFBI-WT-F GTCACTCGAGTCGGTCGCTAGCTCGCTC
  TGFBI-WT-R GTCAAAGCTTCTATGCTTCATCCTCTCTAATAAC
TGFBI-T538P-I TGFBI-WT-F GTCACTCGAGTCGGTCGCTAGCTCGCTC
  TGFBI-538-R CAAAGACTGG*GTAGACTCCT
TGFBI-R555W-I TGFBI-WT-F GTCACTCGAGTCGGTCGCTAGCTCGCTC
  TGFBI-555-R AGTCTGCTCCA*TTCTCTTGG
TGFBI-T538P-II TGFBI-538-F AGGAGTCTACC*CAGTCTTTG
  TGFBI-WT-R GTCAAAGCTTCTATGCTTCATCCTCTCTAATAAC
TGFBI-R555W-II TGFBI-555-F CCAAGAGAAT*GGAGCAGACT
  TGFBI-WT-R GTCAAAGCTTCTATGCTTCATCCTCTCTAATAAC
TGFBI TGFBI-qPCR-F AGGACTGACGGAGACCCTCAAC
  TGFBI-qPCR-R TCCGCTAACCAGGATTTCATCAC
GAPDH GAPDH-F CAGGGCTGCTTTTAACTCTGG
  GAPDH-R TGGGTGGAATCATATTGGAACA
*: site of introduced mutation.
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115830 min, the membrane was incubated with the secondary
antibody for 1 h at room temperature.
A mouse anti-c-myc-tag monoclonal antibody (1:750;
GenScript,  Piscataway,  NJ)  and  a  rabbit  anti-TGFBIp
polyclonal antibody (1:750; Santa Cruz Biotechnology, Santa
Cruz, CA) were used to detect the TGFBI-myc fusion protein.
Mouse anti-GRP78 monoclonal antibody (1:500; Santa Cruz
Biotechnology) was used to detect GRP78. Goat antimouse
immunoglobulin (IgG; H&L; [HPR] 1:2,000; GenScript) and
goat  antirabbit  IgG  (HPR;  1:2,000;  Santa  Cruz
Biotechnology) were used as secondary antibodies. Rabbit
anti-β-actin antibody (1:2,000; Santa Cruz Biotechnology)
was used to determine the amount of β-actin to ensure equal
amounts  of  protein  were  loaded  in  each  lane  for
electrophoresis.  Immunostaining  was  visualized  with
enhanced chemiluminescence (ECL, Biologic Industries, Beit
Haemek,  Israel).  The  signal  intensity  of  the  bands  was
analyzed with Quantity One 1-D analysis software (Bio-Rad,
Hercules, CA).
Quantitative  real-time  reverse  transcription  polymerase
chain reaction: Total RNA was extracted from HCE and HeLa
cells using RNAiso Plus (TaKaRa, Dalian, China) according
to the manufacturer’s protocol. cDNA was synthesized by
reverse transcription using the PrimeScript RT Reagent Kit
(TaKaRa).  RT–PCR  was  performed  in  a  total  volume  of
20 μl reaction mixture containing 500 ng total RNA, 4 μl 5×
PrimeScript Buffer, 1 μl PrimeScript RT Enzyme Mix I, 1 μl
oligo dT primer (50 μM), and 1 ml Random 6 mers (100 μM).
The mixture was incubated at 37 °C for 15 min followed by
5-s inactivation at 85 °C. Real-time PCR was performed in a
10 μl reaction mixture containing 5 μl SYBR Premix Ex Taq,
0.2 μl of each primer (10 μM; Table 1), 0.2 μl ROX reference
dye,  and  1  μl  of  the  cDNA  sample.  Amplification  was
performed on an ABI 7900 instrument (Applied Biosystems,
Foster City, CA). The thermocycling program included initial
denaturation at 95 °C for 10 min, followed by 40 cycles of
95 °C for 5 s and 60 °C for 30 s. Glyceraldehydes 3-phosphate
dehydrogenase (GAPDH) was selected as a reference gene.
Data were analyzed using the comparative cycle threshold
method.
Statistical  analyses:  The  post-hoc  test  for  multiple
comparisons after one-way ANOVA was Tukey test was used
to determine the intensity ratio differences. A p<0.05 was used
to determine significant differences between the groups.
RESULTS
Mutant  plasmids  construction:  To  construct  the  mutant
pcTGFBI-T538P/R555W-myc  plasmid,  the  two-sequential
PCR site-directed mutagenesis technique was used. Agarose
gel  electrophoresis  showed  a  clear  band  with  a  size
corresponding to approximately 2 kb after the second PCR
(Figure 3A; lanes 1, 2). This corresponded with the size of the
full-length  TGFBI  cDNA.  The  wild-type  and  mutant
pcTGFBI plasmids were double digested with Xho I/Hind III.
As  expected,  each  plasmid  was  cut  into  2-kb  and  5.5-kb
fragments (Figure 3B). The sequences of all the constructs
were also verified with direct sequencing. The results clearly
showed that A was replaced with C at position c.1613 of the
Figure 2. Schematic representation of
the recombinant mutant TGFBI proteins
and the principal of the two-sequential
PCR  site-directed  mutagenesis
technique. A: S: signal sequence, EMI:
cysteine-rich EMI domain, I to IV: four
FAS1  domains,  RGD:  Arg-Gly-Asp
domain, Myc: myc tag protein, TGFBI-
T538P-I: bp 1 to 1613 (the 538 mutant
site), TGFBI-R555W-I: bp 1 to 1663 (the
555  mutant  site),  TGFBI-T538P/
R555W-II: from the mutant site to the 3′
end of the sequence. B: The rectangle
represents the template DNA, the circle
in the rectangle represents the mutant
site, and the arrow represents the primer.
In  the  first  PCR,  TGFBI-T538P/
R555W-I  were  amplified  with  the
TGFBI-WT-F  and  TGFBI-T538P/
R555W-R  primers.  TGFBI-T538P/
R555W-II  were  amplified  with  the
TGFBI-T538P/ R555W-F and TGFBI-
WT-R primers. In the second PCR, full-
length  TGFBI-T538P/  R555W  were
amplified  with  the  TGFBI-WT-F  and
TGFBI-WT-R primers.
Molecular Vision 2012; 18:1156-1164 <http://www.molvis.org/molvis/v18/a121> © 2012 Molecular Vision
1159T538P plasmid, while T substituted C at c.1663 of the R555W
plasmid (Figure 3C). Aside from the induced point mutation,
there were no other mutations throughout the entire sequence.
Arg555Trp and Thr538Pro mutant TGFBI proteins resist C-
terminal cleavage: To investigate the expression of the wild-
type and mutant TGFBI-myc fusion proteins, HCE and HeLa
cells  were  used  for  transient  plasmid  transfection.  Each
protein expressed a Myc tag at its C-terminus. In Figure 4A,
65 µg protein from the media of HCE cells was loaded into
each well. As expected, the wild-type TGFBI-myc protein
was not detected by an anti-c-myc-tag antibody due to C-
terminal cleavage (lane 2). This was consistent with Kim et
al.’s study, which indicated that wild-type TGFBI undergoes
C-terminal  cleavage  processing  after  secretion  [11].
Surprisingly,  TGFBI-T538P-myc  (lane  3)  and  TGFBI-
R555W-myc (lane 4) fusion proteins were detected by anti-c-
myc-tag antibody at approximately 70 kDa.
The same samples were immunoblotted with an anti-
TGFBI antibody (Figure 4B). First, the wild-type and mutant
type TGFBI-myc fusion proteins were detected as two bands
of different intensities (lanes 2–4). An endogenous TGFBIp
was seen in the control lane (lane 1), but it was much weaker
than the recombinant wild-type TGFBIp. Second, the smaller
wild-type TGFBIp band was much stronger than the larger
one, while the opposite was observed for the mutant TGFBI
protein. Furthermore, there was an approximately 10 kDa
difference between the two bands, indicating that the cleavage
site may be 10 kDa away from the C-terminal end of the
protein.
These  results  were  replicated  in  HeLa  cells  (Figure
4C,D), reinforcing that the mutant TGFBI escapes C-terminal
cleavage after secretion.
Effect of mutation and cell type on TGFBIp expression: To
compare the expression level of TGFBIp-myc in HCE and
HeLa cells, an equal amount of protein (70 μg) was collected
from the media of these cells after transfection and subjected
to electrophoresis. The blot showed that there was more full-
length  TGFBI-T538P/R555W-myc  protein  in  HCE  cells
compared  with  HeLa  cells  (Figure  5).  In  addition,  the
endogenous levels of the TGFBI gene expressed in both cell
lines were checked with quantitative real-time RT–PCR. The
results  showed  the  expression  levels  of  the  endogenous
TGFBI gene of the HCE cells were higher than those of the
HeLa cells (data not shown). Moreover, the expression levels
of the TGFBI-R555W-myc protein were higher than those of
the TGFBI-T538P-myc protein, indicating that the mutation
also had an effect on protein expression.
Arg555Trp  and  Thr538Pro  mutant  TGFBI  proteins  are
unlikely  to  induce  endoplasmic  reticulum  stress:  The
expression of the ER stress molecular chaperone GRP78/BiP
was  analyzed  to  investigate  ER  stress  after  transfection.
Intracellular proteins were collected from HeLa cells at 12,
24, and 48 h after transfection with different plasmids. An
equal amount of protein was subjected to electrophoresis. No
significant differences were found between the mutant and
wild-type groups at 12 and 48 h (p>0.05; Figure 6A, C,D).
The intensity ratio of the T538P group was slightly lower than
Figure  3.  Construction  of  mutant
plasmids.  A:  PCR  products  of  the
recombinant mutant TGFBI-T538P and
TGFBI-R555W genes. M: 1 kb marker
(Fermentas, Burlington, Canada), lane
1:  TGFBI-T538P,  lane  2:  TGFBI-
R555W. B: Constructed pcTGFBI-WT/
T538P/R555W-myc  plasmids  were
double  digested  into  two  bands
approximately  2  kb  and  5.5  kb,
respectively, using Xho I and Hind III.
M: 1 kb marker, lane 1: pcTGFBI-WT-
myc, lane 2–lane 3: pcTGFBI-T538P-
myc, lane 4–lane 5: pcTGFBI-R555W-
myc. C: Right: Partial sequence of the
pcTGFBI-T538P plasmid showing the
A to C change at position c.1613 (the
forward strand is shown) resulting in the
p.Thr538Pro  mutation  (underlined).
Left: Partial sequence of the pcTGFBI-
R555W  plasmid  showing  the  C  to  T
mutation at position c.1663 (the forward
strand  is  shown)  resulting  in  the
p.Arg555Trp  mutation  (underlined).
The arrow points toward the position of
the mutations.
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1160the wild-type group at 24 h (p=0.003; Figure 6B,D). However,
this transient fluctuation returned to the same level as the wild-
type group after 48 h. The expression of GRP78/BiP at 48 h
was significantly higher than that at 12 and 24 h (p<0.05;
Figure  6).  In  the  positive  control  group,  GRP78/BiP
expression was significantly increased in the tunicamycin-
treated cells compared with the untreated cells (Figure 6E).
DISCUSSION
To gain insight into the mechanism underlying TGFBI-related
corneal dystrophies, we first investigated the influence of the
Arg555Trp and Thr538Pro TGFBI mutant proteins on C-
terminal  cleavage  and  ER  stress.  In  this  study,  we
demonstrated  that  the  Arg555Trp/Thr538Pro  mutations
prevent the C-terminal cleavage of TGFBIp.
Figure 4. Western blot analysis of the recombinant wild-type and mutant proteins. HCE and HeLa cells (A, B: HCE cell; C, D: HeLa cells)
were transfected with wild-type (lane 2) and two mutant TGFBI plasmids (lanes 3 and 4) or were not transfected plasmid (lane 1). The culture
medium was replaced with serum-free medium 48 h post-transfection. Another 48 h later, the serum-free media from overexpressed cells were
collected and concentrated. A and C: 65 µg protein was loaded into each well. The TGFBI-T538P-myc and TGFBI-R555W-myc protein were
detected with an anti-c-myc-tag antibody (lanes 3 and 4), while the wild-type TGFBI-myc protein was not (lane 2). B and D: 65 µg protein
was loaded on to each well and detected with an anti-TGFBIp antibody. The wild-type and mutant TGFBI-myc fusion proteins were detected
as two bands of different intensities (lanes 2–4). Endogenous TGFBIp is shown in the control lane (lane 1). The stronger bands in lanes 3 and
4 represent full-length mutant TGFBI-myc proteins, while the stronger band in lane 2 represents the wild-type TGFBI-myc protein that lacks
its C-terminus. There was an approximate 10 kDa difference between the full-length and cleaved proteins.
Figure 5. Comparison of the amount of recombinant TGFBI secreted from HCE and HeLa cells. HCE and HeLa cells (lane 1–lane 4: HCE,
lane 5–lane 8: HeLa cells) were transfected with wild-type (WT) and the two mutant TGFBI plasmids. Control represents HCE or HeLa cells
without transfection with plasmids. Media from overexpressed cells were collected and analyzed with an anti-myc antibody. The expression
level of the R555W mutant protein was much higher than that of the T538P mutant protein. Moreover, the HCE cells expressed more full-
length mutant protein than the HeLa cells. This result indicates the cell type and mutation affect the TGFBIp expression level.
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was detected only by an anti-TGFBI antibody but not by an
anti-myc antibody (Figure 4, lane 2). This demonstrated that
the wild-type TGFBI underwent C-terminal cleavage after
secretion, and the major form of TGFBIp in the medium
lacked its C-terminal. The control lane without any plasmid
transfection (Figure 4B, D, lane 1) also showed a faint band
when detected by the anti-TGFBI antibody. This could be
because HeLa or HCE cells secrete endogenous TGFBIp but
at much lower levels than the recombinant wild-type TGFBIp.
In addition, the size of the weak band was the same as that of
recombinant  wild-type  TGFBIp,  indicating  that  the
endogenous TGFBIp also undergoes C-terminal processing.
These results were consistent with previous studies. A study
previously  reported  that  recombinant  wild-type  TGFBIp
expressed in Chinese hamster ovary cells lacked its RGD
sequence, suggesting a C-terminal processing reaction [13],
which was later demonstrated by a Korean research group
[11]. An in vivo study also found that the majority of TGFBIp
in normal human corneas was C-terminally truncated after the
RGD sequence [12].
Moreover,  we  found  an  exciting  phenomenon:  the
Arg555Trp and Thr538Pro mutant TGFBIp was detected by
an anti-Myc antibody and an anti-TGFBI antibody (Figure 4,
lanes 3, 4). When proteins were immunoblotted with the anti-
TGFBI antibody, two bands with different intensities were
seen in each lane (Figure 4B, D, lanes 3, 4). The stronger band
represented  the  full-length  approximately  70  kDa  mutant
TGFBIp. The weaker band represented endogenous TGFBIp
because the intensity was the same as the control lane. This
indicated that the Arg555Trp and Thr538Pro mutant TGFBIp
was  resistant  to  C-terminal  cleavage,  and  the  full-length
mutant TGFBIp was the major form in the medium. This is
the first time the difference between the C-terminal cleavage
of mutant and wild-type TGFBIp has been shown.
The C-terminal cleavage of wild-type TGFBIp is thought
to be a heterogeneous event leading to a truncated C-terminus
[12]. However, the cleavage always occurs either upstream or
Figure 6. Western blot analysis of GRP78/BiP. HeLa cells were harvested at 12 (A), 24 (B), and 48 (C) h after transfection with the pcTGFBI-
WT-myc (WT), pcTGFBI-T538P-myc (T538P), and pcTGFBI-R555W-myc (R555W) plasmids. The proteins were separated on 8% SDS-
polyacrylamide gels, transferred, and probed with an anti-GRP 78 antibody. The amount of β-actin was analyzed with an anti-β-actin antibody
to ensure that equal amounts of protein were loaded in each lane for electrophoresis. The intensity ratio was calculated by the intensity of the
GRP78 band divided by the intensity of the β-actin band (D). No significant differences were found between the mutant and wild-type groups
at 12 and 48 h (p>0.05). The intensity ratio of the T538P group was slightly lower than the wild-type group at 24 h (p=0.003). This transient
fluctuation returned to the same level as the wild-type group after 48 h. The expression of GRP78/BiP at 48 h was significantly higher than
that at 12 and 24 h (p<0.05). In the positive control group, GRP78/BiP expression was significantly increased in the tunicamycin-treated cells
compared with the untreated cells (E).
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1162downstream of the integrin-binding RGD peptides. In this
study, the RGD peptide was approximately 7 kDa from the C-
terminus  of  the  recombinant  fusion  protein.  There  was  a
difference of approximately 10 kDa between the full length
and the cleavage proteins (Figure 4B,D), which supports the
idea that the cleavage occurred near the RGD peptide. If the
cleavage occurred before the RGD, the C-terminal fragment
released from TGFBI containing the RGD sequence would
mediate apoptosis [11]. On the contrary, if the processing
occurred after the RGD sequence, it may make the area around
the  RGD  peptide  more  accessible,  thereby  triggering  the
integrin  binding  activity  [12,24].  Integrins  are  functional
receptors that mediate the attachment of cells to the ECM or
cell-cell interaction by recognizing certain sequences, such as
the RGD peptide. A study reported that TGFBIp mediates
HCE cell adhesion through α3β1 integrin [25]. According to
these studies, C-terminal processing is an important event in
TGFBIp function. We suspected that the mutations preventing
TGFBIp  cleavage  would  disrupt  the  interaction  between
TGFBIp  and  integrin,  thereby  resulting  in  disease
development (Figure 1).
Secondary  structural  predictions  show  that  mutations
possibly leading to misfolding of TGFBIp would result in
complete structural disruption [14,26,27]. The ER is the first
compartment in the secretory pathway. All secretory proteins
enter the ER for synthesis, modification, and folding [15].
After translation, TGFBIp is transported into the ER guided
by the N-terminal signal sequences. After folding in the ER,
TGFBIp is transported to the Golgi for further modifications.
This processing was demonstrated with immunofluorescence
microscopy in a recent study [28]. Accumulation of misfolded
proteins increases cell ER stress, which has been found to be
associated with disease development. A study on diabetic
retinopathy  showed  that  a  high  concentration  of  glucose
increases ER stress and induces the UPR in retinal pericytes
[29]. Another study reported that accumulation of mutant Rh1
(rhodopsin-1) protein increases cell ER stress in a fly model
for  RhodopsinPro23His  human  retinitis  pigmentosa  [21].
Overexpression of mutant superoxide dismutase 1 (SOD1),
which could result in amyotrophic lateral sclerosis, causes the
upregulation of GRP78/BiP expression in COS7 cells and
transgenic mice [30]. Investigation of the influence of TGFBI
mutations on cell ER stress would help to characterize the
mechanisms  underlying  TGFBI-related  corneal  dystrophy.
GRP78/BiP, the major ER stress molecular chaperone, is a
peptide-dependent  ATPase  that  binds  to  UPR  transducers
under  non-stressed  conditions.  When  misfolded  proteins
accumulate in the cells, GRP78/BiP dissociates from the UPR
transducers  to  chaperone  these  misfolded  proteins  and
activates one or more transducers simultaneously [22]. This
is the first event in signal transduction in response to the
accumulation of unfolded proteins in the ER [15].
In this study, we analyzed the GRP78/BiP expression
levels of HeLa cells at 12, 24, and 48 h after transfection with
the  pcTGFBI-WT/T538P/R555W-myc  plasmids.  No
significant differences were found between the mutant and
wild-type groups at 12 and 48 h (p>0.05; Figure 6A,C,D). The
intensity ratio of the T538P group was slightly lower than the
wild-type group at 24 h (p=0.003; Figure 6B,D). However,
this transient fluctuation returned to the same level as the wild-
type  group  after  48  h.  This  result  indicated  that  the
p.Arg555Trp and p.Thr538Pro mutant TGFBI proteins do not
upregulate or downregulate GRP78/BiP expression compared
with  the  wild-type  TGFBIp,  suggesting  that  these  two
mutations of TGFBIp were unlikely to disrupt protein folding
or that the disruption could be repaired by the UPR in the cells.
This was consistent with the Kim et al.’s [31] study, which
reported that the mutant forms of TGFBI commonly found in
TGFBI-linked corneal dystrophies did not significantly affect
the fibrillar structure visualized with electron microscopy.
They suggested it was unlikely that a single point mutation of
TGFBI significantly affects the whole protein structure.
In  conclusion,  we  demonstrated  that  Arg555Trp  and
Thr538Pro  mutations  prevent  TGFBIp  from  C-terminal
cleavage and are unlikely to induce cell ER stress. This is the
first time that a difference between the C-terminal cleavage
of  mutant  and  wild-type  TGFBIp  has  been  demonstrated.
Although the mechanism underlying TGFBI-related corneal
dystrophies is still unclear, we suspect that corneal dystrophy–
related mutations are more likely to disrupt the interaction of
TGFBI with critical binding proteins rather than altering the
entire protein structure.
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